124 related articles for article (PubMed ID: 8490900)
1. A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma.
Flaherty LE; Robinson W; Redman BG; Gonzalez R; Martino S; Kraut M; Valdivieso M; Rudolph AR
Cancer; 1993 Jun; 71(11):3520-5. PubMed ID: 8490900
[TBL] [Abstract][Full Text] [Related]
2. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.
Atkins MB; O'Boyle KR; Sosman JA; Weiss GR; Margolin KA; Ernest ML; Kappler K; Mier JW; Sparano JA; Fisher RI
J Clin Oncol; 1994 Aug; 12(8):1553-60. PubMed ID: 8040667
[TBL] [Abstract][Full Text] [Related]
3. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
[TBL] [Abstract][Full Text] [Related]
4. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma.
Guida M; Latorre A; Mastria A; De Lena M
Eur J Cancer; 1996 Apr; 32A(4):730-3. PubMed ID: 8695281
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma.
Steffens TA; Bajorin DF; Chapman PB; Lovett DR; Cody-Johnson BV; Templeton MA; Heelan RT; Wong GY; Portlock CS; Oettgen HF
Cancer; 1991 Sep; 68(6):1230-7. PubMed ID: 1873774
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of combined administration of dacarbazine and carboplatin with home therapy of recombinant interleukin-2 and interferon-alpha 2a in patients with advanced malignant melanoma.
Ron IG; Mordish Y; Eisenthal A; Skornick Y; Inbar MJ; Chaitchik S
Cancer Immunol Immunother; 1994 Jun; 38(6):379-84. PubMed ID: 8205559
[TBL] [Abstract][Full Text] [Related]
8. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.
Legha SS; Ring S; Eton O; Bedikian A; Buzaid AC; Plager C; Papadopoulos N
J Clin Oncol; 1998 May; 16(5):1752-9. PubMed ID: 9586888
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
[TBL] [Abstract][Full Text] [Related]
10. Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma).
Sertoli MR; Queirolo P; Bajetta E; Del Vecchio M; Comella G; Barduagni L; Bernengo MG; Vecchio S; Criscuolo D; Bufalino R; Morabito A; Cascinelli N
Melanoma Res; 1999 Oct; 9(5):503-9. PubMed ID: 10596917
[TBL] [Abstract][Full Text] [Related]
11. A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma.
Flaherty LE; Redman BG; Chabot GG; Martino S; Gualdoni SM; Heilbrun LK; Valdivieso M; Bradley EC
Cancer; 1990 Jun; 65(11):2471-7. PubMed ID: 2337862
[TBL] [Abstract][Full Text] [Related]
12. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
Atkins MB; Gollob JA; Sosman JA; McDermott DF; Tutin L; Sorokin P; Parker RA; Mier JW
Clin Cancer Res; 2002 Oct; 8(10):3075-81. PubMed ID: 12374674
[TBL] [Abstract][Full Text] [Related]
13. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials.
Flaherty LE; Atkins M; Sosman J; Weiss G; Clark JI; Margolin K; Dutcher J; Gordon MS; Lotze M; Mier J; Sorokin P; Fisher RI; Appel C; Du W
J Clin Oncol; 2001 Jul; 19(13):3194-202. PubMed ID: 11432886
[TBL] [Abstract][Full Text] [Related]
14. Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I-II study.
Shiloni E; Pouillart P; Janssens J; Splinter T; Di Peri T; Symann M; Roest GJ; Palmer PA; Franks CR
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S45-9. PubMed ID: 2697579
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma.
Gibbs P; Iannucci A; Becker M; Allen J; O'Driscoll M; McDowell K; Williams P; Rosse P; Murphy J; Gonzalez R
Melanoma Res; 2000 Apr; 10(2):171-9. PubMed ID: 10803718
[TBL] [Abstract][Full Text] [Related]
16. High-dose cisplatin plus dacarbazine in the treatment of metastatic melanoma.
Murren JR; DeRosa W; Durivage HJ; Davis C; Makuch R; Portlock CS
Cancer; 1991 Mar; 67(6):1514-7. PubMed ID: 2001539
[TBL] [Abstract][Full Text] [Related]
17. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.
McDermott DF; Mier JW; Lawrence DP; van den Brink MR; Clancy MA; Rubin KM; Atkins MB
Clin Cancer Res; 2000 Jun; 6(6):2201-8. PubMed ID: 10873069
[TBL] [Abstract][Full Text] [Related]
18. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study.
Stoter G; Shiloni E; Aamdal S; Cleton FJ; Iacobelli S; Bijman JT; Palmer P; Franks CR; Rodenhuis S
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S41-3. PubMed ID: 2697578
[TBL] [Abstract][Full Text] [Related]
19. Treatment of metastatic malignant melanoma with 24 hours continuous venous infusion of dacarbazine and cisplatin.
Icli F; Karaoguz H; Dincol D; Gunel N; Demirkazik A
J Surg Oncol; 1991 Nov; 48(3):199-201. PubMed ID: 1943117
[TBL] [Abstract][Full Text] [Related]
20. Biochemotherapy with carmustine, cisplatin, dacarbazine, tamoxifen and low-dose interleukin-2 for patients with metastatic malignant melanoma.
Su PJ; Chen JS; Liaw CC; Chang HK; Wang HM; Yang TS; Lin YC; Liau CT; Yang HY; Yeh KY; Ho MM; Chang NJ; Wang CH; Chang JW
Chang Gung Med J; 2011; 34(5):478-86. PubMed ID: 22035892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
